Risedronic acid [clinicaltrials_resource:1c480ad584c43c5e3b2d54a985f6758e]
clinicaltrials:NCT00043069clinicaltrials:NCT00051636clinicaltrials:NCT00054418clinicaltrials:NCT00082277clinicaltrials:NCT00089843A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) [clinicaltrials:NCT00092014]A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907) [clinicaltrials:NCT00092040]clinicaltrials:NCT00103740clinicaltrials:NCT00106028OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women [clinicaltrials:NCT00130403]Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury [clinicaltrials:NCT00138866]Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury. [clinicaltrials:NCT00150696]Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy [clinicaltrials:NCT00216060]clinicaltrials:NCT00221299clinicaltrials:NCT00244907clinicaltrials:NCT00247273Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients. [clinicaltrials:NCT00266708]IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment) [clinicaltrials:NCT00268632]Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS [clinicaltrials:NCT00324714]clinicaltrials:NCT00343252Risedronate in Osteopenic Postmenopausal Women [clinicaltrials:NCT00345644]Risedronate in Postmenopausal Women With Low Bone Density [clinicaltrials:NCT00351091]Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women [clinicaltrials:NCT00353080]Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial CAN-NCIC-MA27 [clinicaltrials:NCT00354302]Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women [clinicaltrials:NCT00358176]clinicaltrials:NCT00365456The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment [clinicaltrials:NCT00372372]clinicaltrials:NCT00377234clinicaltrials:NCT00386360Risedronate in the Prevention of Osteoporosis in Postmenopausal Women [clinicaltrials:NCT00402441]Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis [clinicaltrials:NCT00405392]Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer [clinicaltrials:NCT00426777]clinicaltrials:NCT00445575A Study of Actonel for the Prevention of Bone Loss [clinicaltrials:NCT00452439]Risedronate Sodium in Post Menopausal Osteoporosis [clinicaltrials:NCT00453492]SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture. [clinicaltrials:NCT00460733]clinicaltrials:NCT00485953clinicaltrials:NCT00503399clinicaltrials:NCT00541658POWER Point of Care Effect on Satisfaction of Treatment [clinicaltrials:NCT00549068]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Risedronic acid [clinicaltrials_resource:1c480ad584c43c5e3b2d54a985f6758e]
Bio2RDF identifier
1c480ad584c43c5e3b2d54a985f6758e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1c480ad584c43c5e3b2d54a985f6758e
identifier
clinicaltrials_resource:1c480ad584c43c5e3b2d54a985f6758e
title
Risedronic acid
@en
type
label
Risedronic acid [clinicaltrials_resource:1c480ad584c43c5e3b2d54a985f6758e]
@en